Association of ABCB1 Polymorphisms with the Antiemetic Efficacy of Granisetron plus Dexamethasone in Breast Cancer Patients

作者：Tsuji Daiki^*; Kim Yong Il; Nakamichi Hidenori; Daimon Takashi; Suwa Kaori; Iwabe Yutaro; Hayashi Hideki; Inoue Kazuyuki; Yoshida Masayuki; Itoh Kunihiko

来源：Drug Metabolism and Pharmacokinetics, 2013, 28(4): 299-304.

DOI：10.2133/dmpk.DMPK-12-RG-084

• ABCB1 polymorphism
• breast cancer
• chemotherapy induced emesis
• granisetron
• doxorubicin
• cyclophosphamide

Resistance to antiemetic treatment with 5-hydroxytryptamine 3 receptor antagonists is a problem, with 20-30% of patients showing unsatisfactory responses. Efflux transport by P-glycoprotein, encoded by the ATP-binding cassette ABCBI gene in the blood brain barrier, has been the suggested resistance mechanism. We evaluated the association between the antiemetic efficacy of granisetron plus dexamethasone and ABCB1 polymorphisms 3435C%26gt; T and 2677G%26gt; T/A. Sixty-four breast cancer patients treated with doxorubicin plus cyclophosphamide were evaluated for their responses to antiemetic therapy. Genotyping of patient DNA samples for ABCB1 single nucleotide polymorphisms was performed; the genotypes were then investigated for their association with the efficacy of prophylactic antiemetics. The acute phase complete response rate was 83% in GG subjects (n = 12), and 69% (n = 35) and 41% (n = 17) in heterozygous and homozygous carriers of the 2677T/A allele, respectively (p = 0.047). The ABCBI 2677 TT genotype group showed significantly lower rates of complete control of acute emesis than the group with GG genotypes (p = 0.045). No significant association with complete response was found for 3435C%26gt;T (p = 0.190). ABCB1 polymorphisms may influence the extent of acute emesis control in granisetron-treated patients, making the ABCBI genotype a predictor of prophylactic antiemetic response.

• 出版日期2013-8-25